

## PMC SCIENCE AND PUBLIC POLICY COMMITTEES MEETING AGENDA

Thursday, September 24, 12:00 – 2:00 p.m. ET

Link to webinar:

<https://permedcoalition.webex.com/permedcoalition/onstage/g.php?MTID=e4426c64095a4215ce789ae0c43d5b29b>  
(passcode: pmc123)

Dial 202-800-9984 and enter meeting ID 825756

### 12:00 p.m. ET Welcome & Introduction

#### **Edward Abrahams**

President

Personalized Medicine Coalition

### 12:10 p.m. ET Advancing Genomic Testing and Patient Priorities for Personalized Medicine

#### **David Davenport**

Manager, Public Policy & Secretary to the Board

Personalized Medicine Coalition

- [\*Moving Beyond Population Averages: A Patient-Centered Research Agenda Advancing Personalized Medicine\*](#)
  - [Overview](#)
  - [PMC press release](#) (August 21, 2020)

#### **Daryl Pritchard, Ph.D.**

Senior Vice President, Science Policy

Personalized Medicine Coalition

- [\*Understanding Genomic Testing Utilization and Coverage in the US\*](#)
  - [PMC press release](#) (August 7, 2020)

12:40 p.m. ET **Business Meeting**

**Daryl Pritchard, Ph.D.**

Senior Vice President, Science Policy

Personalized Medicine Coalition

- **Science Policy Updates**

- ***The Personalized Medicine Report: Opportunity, Challenges, and the Future (6<sup>th</sup> Edition)***
- **[Understanding and Delivering the Clinical and Economic Benefits of Personalized Medicine: A Research Program](#)**
  - *Addressing Practice Gaps in the Implementation of Personalized Medicine in Cancer Care*
- **Pharmacogenomics**
  - *Pharmacogenomics in Clinical Guidelines and at FDA*
  - *STRIFE: A Collaborative Community in Pharmacogenomics*
- **Working Group Updates**
  - Pharmacogenomics Working Group
  - Health Care Working Group

**Cynthia A. Bens**

Senior Vice President, Public Policy

Personalized Medicine Coalition

- **Public Policy Updates**

- **Congressional Activities**
  - Congressional Personalized Medicine Caucus
  - FY 2021 Appropriations for National Institutes of Health and the Food and Drug Administration
    - [PMC Outside Witness Testimonies](#) (submitted March – April 2020)
- **Regulation**
  - User fee program re-authorization
    - [PMC's Remarks on Patient Panel During FDA's Public Workshop on the Seventh Reauthorization of the Prescription Drug User Fee Act](#) (delivered July 23, 2020)
    - Medical device user fee program reauthorization public meeting
- **Coverage and Reimbursement**
  - "Most favored nations" executive order on reference pricing
  - Update on establishing a MS-DRG for CAR T-cell therapies
    - [PMC comment letter](#) (July 10, 2020)

- National coverage analysis for blood-based biomarker screening tests for colorectal cancer
    - [PMC comment letter](#) (March 27, 2020)
  - Proposed OPPS rule and “Laboratory Date of Service Policy”
    - For reference: [PMC comment letter](#) (September 27, 2019)
  - Medicare coverage of innovative technology (MCIT) pathway for breakthrough devices (see [Federal Register notice](#))
- **Working Group Updates**
    - Pharmaceutical & Diagnostics Working Group
    - Patient Advocacy Organization Working Group
- **Planning for 2021**
    - *2021 Policy Agenda*
    - *2021 Strategic Plan*
    - 2021 Planning Discussion Questions
      - [Download the complete list of questions](#) (feedback due October 6)

Selected Questions for Discussion

1. From your perspective are there any **new, or high-priority, policy issues** impacting personalized medicine that the coalition should consider engaging in 2021? Are there any issues that have the potential to emerge as a high priority? *Note: You can find PMC’s 2020 Policy Agenda [here](#) and an archive of PMC’s comments on an array of policy issues [here](#).*
2. Given the long-term impact **COVID-19** may have on the health system and patient care, as well as personalized medicine, where do you think PMC could be most effective in engaging related policy discussions to advocate for personalized medicine?
3. **Diversity, equity and inclusion** are important issues impacting patients’ access to personalized medicine. How can PMC be helpful in promoting diversity, equity and inclusion in personalized medicine, both in medical research and health care delivery?
4. PMC’s **evidence development program** currently has eight projects in various states of progress to generate evidence supporting the clinical and economic utility of personalized medicine in multiple disease states. Do you have suggestions for future projects that would support the evidence base for personalized medicine?

**1:50 p.m. ET      New Business**

**2:00 p.m. ET      Conclusion**

- **Upcoming PMC Policy Meetings**
  - December 15, 2020, 12:00 – 2:00 p.m. ET (new date)